Takeda can't avoid evidence in US antitrust case over Amitiza, plaintiffs say
MLex Summary: End-payor plaintiffs opposed judgment in favor of Takeda Pharmaceuticals in a US case accusing it of illegally delaying generic competition to its brand name drug Amitiza. They argued that all...To view the full article, register now.
Already a subscriber? Click here to view full article